Advancing Next Gen Antibodies And ADCs: From AI Driven Cell Line Development To Integrated Manufacturing

Rising molecular complexity in antibody-drug conjugates is reshaping how development teams approach every stage of CMC strategy. Integrating data-driven workflows with AI-enabled tools is helping accelerate timelines while improving confidence in product quality and manufacturability. Advances in cell line development are enabling faster clone selection, boosting productivity, and revealing potential risks earlier—supporting more informed decision-making from the outset.

From early process development through scale-up and commercial readiness, new approaches are aligning development and manufacturing to deliver greater consistency and efficiency. As modalities like multispecific antibodies and ADCs continue to evolve, emerging technologies focused on digital connectivity and process integration are paving the way for more predictive, streamlined bioproduction.

Learn how these innovations can help de-risk programs and prepare complex therapies for long-term success.